Last reviewed · How we verify
Rohr and Columbo Asthma, Allergy and Immunology Specialists, P.C. — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
0 Phase 3
1 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
Therapeutic area mix
- Immunology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Actavis Mid-Atlantic LLC · 1 shared drug class
- Active Biotech AB · 1 shared drug class
- Air Force Military Medical University, China · 1 shared drug class
- Astellas Pharma Inc · 1 shared drug class
- Bayer · 1 shared drug class
- Beijing Children's Hospital · 1 shared drug class
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences · 1 shared drug class
- ALK-Abelló A/S · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Rohr and Columbo Asthma, Allergy and Immunology Specialists, P.C.:
- Rohr and Columbo Asthma, Allergy and Immunology Specialists, P.C. pipeline updates — RSS
- Rohr and Columbo Asthma, Allergy and Immunology Specialists, P.C. pipeline updates — Atom
- Rohr and Columbo Asthma, Allergy and Immunology Specialists, P.C. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Rohr and Columbo Asthma, Allergy and Immunology Specialists, P.C. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/rohr-and-columbo-asthma-allergy-and-immunology-specialists-p-c. Accessed 2026-05-16.